- Home
- INSM vs BMRN Comparison
INSM vs BMRN Comparison
Compare INSM & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- BMRN
- Stock Information
- Founded
- INSM 1988
- BMRN 1996
- Country
- INSM United States
- BMRN United States
- Employees
- INSM N/A
- BMRN N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- INSM Health Care
- BMRN Health Care
- Exchange
- INSM Nasdaq
- BMRN Nasdaq
- Market Cap
- INSM 12.6B
- BMRN 12.1B
- IPO Year
- INSM 2000
- BMRN 1999
- Fundamental
- Price
- INSM $66.76
- BMRN $61.00
- Analyst Decision
- INSM Strong Buy
- BMRN Buy
- Analyst Count
- INSM 16
- BMRN 22
- Target Price
- INSM $95.29
- BMRN $93.43
- AVG Volume (30 Days)
- INSM 2.6M
- BMRN 1.6M
- Earning Date
- INSM 05-08-2025
- BMRN 05-01-2025
- Dividend Yield
- INSM N/A
- BMRN N/A
- EPS Growth
- INSM N/A
- BMRN 152.82
- EPS
- INSM N/A
- BMRN 2.71
- Revenue
- INSM $381,030,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- INSM $30.36
- BMRN $12.27
- Revenue Next Year
- INSM $115.55
- BMRN $9.86
- P/E Ratio
- INSM N/A
- BMRN $21.76
- Revenue Growth
- INSM 20.77
- BMRN 19.36
- 52 Week Low
- INSM $21.92
- BMRN $52.93
- 52 Week High
- INSM $84.91
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- INSM 42.27
- BMRN 46.87
- Support Level
- INSM $63.81
- BMRN $58.74
- Resistance Level
- INSM $73.39
- BMRN $61.26
- Average True Range (ATR)
- INSM 2.56
- BMRN 1.96
- MACD
- INSM -0.33
- BMRN 0.07
- Stochastic Oscillator
- INSM 35.70
- BMRN 36.41
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.